Literature DB >> 23637649

Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Azucena Castrillo1, Marcia Cardoso, Lindsay Rouse.   

Abstract

BACKGROUND: The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet light and is currently approved and used in Europe for the treatment of platelets and plasma. Mirasol treatment is intended to reduce the infectious pathogen load and to inactivate leukocytes in blood products. Our objective was to evaluate buffy coat platelet concentrates (BCPCs) prepared with platelet additive solution (PAS) and treated with the Mirasol system and to examine the effects on platelet cell quality during storage.
METHODS: 26 BCPCs were prepared and split, creating 13 paired control and test units. The test units were treated with the Mirasol system and the platelet quality was assessed in all units over 7 days of storage.
RESULTS: All products met the incoming specifications for Mirasol treatment, and the pH of all Mirasol-treated BCPCs in PAS met the requirements of the Council of Europe guidelines throughout storage. Analysis of lactate production and glucose consumption rates, CD62p expression and cytokines indicates enhanced cellular metabolism in treated platelets, but the levels were within previously published ranges.
CONCLUSION: While Mirasol-treated BCPCs in PAS had increased metabolism and activation compared to controls, the results indicate that these units can be stored for 7 days with acceptable cell quality.

Entities:  

Keywords:  Buffy coat platelets; Mirasol; PAS-IIIM; Pathogen reduction technology

Year:  2013        PMID: 23637649      PMCID: PMC3635978          DOI: 10.1159/000345679

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  20 in total

1.  In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.

Authors:  Sisse R Ostrowski; Louise Bochsen; José A Salado-Jimena; Henrik Ullum; Inge Reynaerts; Raymond P Goodrich; Pär I Johansson
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

2.  A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.

Authors: 
Journal:  Transfusion       Date:  2010-11       Impact factor: 3.157

3.  Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.

Authors:  Sisse R Ostrowski; Louise Bochsen; Nis A Windeløv; José A Salado-Jimena; Inge Reynaerts; Raymond P Goodrich; Pär I Johansson
Journal:  Transfusion       Date:  2010-08-16       Impact factor: 3.157

4.  Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants.

Authors:  Hiroshi Asano; Chih-Yuan Lee; Karen Fox-Talbot; Cheryl M Koh; Melek M Erdinc; Susanne Marschner; Shawn Keil; Raymond P Goodrich; William M Baldwin
Journal:  Transplantation       Date:  2007-11-15       Impact factor: 4.939

Review 5.  Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.

Authors:  Kathryn E Webert; Christine M Cserti; Judy Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman
Journal:  Transfus Med Rev       Date:  2008-01

Review 6.  Pathogen reduction of blood components.

Authors:  Bjarte G Solheim
Journal:  Transfus Apher Sci       Date:  2008-07-03       Impact factor: 1.764

7.  In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.

Authors:  A D Michelson; M R Barnard; H B Hechtman; H MacGregor; R J Connolly; J Loscalzo; C R Valeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

8.  Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Authors:  Susanne Marschner; Raymond Goodrich
Journal:  Transfus Med Hemother       Date:  2011-01-31       Impact factor: 3.747

9.  Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007.

Authors:  Cécile Brouard; Pascale Bernillon; Isabelle Quatresous; Josiane Pillonel; Azzedine Assal; Henriette De Valk; Jean-Claude Desenclos
Journal:  Transfusion       Date:  2008-02-22       Impact factor: 3.157

10.  Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

Authors:  S M Picker; L Oustianskaia; V Schneider; B S Gathof
Journal:  Vox Sang       Date:  2009-03-18       Impact factor: 2.144

View more
  9 in total

Review 1.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

2.  Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela.

Authors:  M Dolores Vilariño; Azucena Castrillo; Alfredo Campos; Rachel Kilian; Mercedes Villamayor; Marcia Cardoso
Journal:  Transfus Med Hemother       Date:  2016-10-28       Impact factor: 3.747

3.  Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.

Authors:  Carme Ballester-Servera; Teresa Jimenez-Marco; Daniel Morell-Garcia; Miguel Quetglas-Oliver; Antonia M Bautista-Gili; Enrique Girona-Llobera
Journal:  Blood Transfus       Date:  2020-05-15       Impact factor: 3.443

Review 4.  Biomanufacturing for clinically advanced cell therapies.

Authors:  Ayesha Aijaz; Matthew Li; David Smith; Danika Khong; Courtney LeBlon; Owen S Fenton; Ronke M Olabisi; Steven Libutti; Jay Tischfield; Marcela V Maus; Robert Deans; Rita N Barcia; Daniel G Anderson; Jerome Ritz; Robert Preti; Biju Parekkadan
Journal:  Nat Biomed Eng       Date:  2018-06-11       Impact factor: 25.671

5.  Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation.

Authors:  Lacey Johnson; Denese Marks
Journal:  Transfus Med Hemother       Date:  2015-05-07       Impact factor: 3.747

Review 6.  Platelet MicroRNAs: An Overview.

Authors:  Neetu Dahiya; Tewarit Sarachana; Long Vu; Kevin G Becker; William H Wood; Yongqing Zhang; Chintamani D Atreya
Journal:  Transfus Med Rev       Date:  2015-08-10

7.  Haemostatic profile of riboflavin-treated apheresis platelet concentrates.

Authors:  Eleni Petrou; Georgios K Nikolopoulos; Anastasios G Kriebardis; Katerina Pantavou; Electra Loukopoulou; Andreas G Tsantes; Hara T Georgatzakou; Eirini Maratou; Evdoxia Rapti; Sofia Mellou; Styliani Kokoris; Argyri Gialeraki; Argirios E Tsantes
Journal:  Blood Transfus       Date:  2021-05-21       Impact factor: 5.752

Review 8.  Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion.

Authors:  Daniel Tzu-Bi Shih; Thierry Burnouf
Journal:  N Biotechnol       Date:  2014-06-11       Impact factor: 5.079

9.  In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.

Authors:  Nicolas Malvaux; Fanette Defraigne; Styliani Bartziali; Camille Bellora; Kathleen Mommaerts; Fay Betsou; Anne Schuhmacher
Journal:  Pathogens       Date:  2022-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.